Name: Medio Oriente y África Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033
Creator: Data Bridge Market Research
License: https://www.databridgemarketresearch.com/privacy-policy

Middle East And Africa Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) : 6.90 %

USD 63.58 Million USD 102.78 Million 2025 2033

Período de pronóstico	2026 –2033
Tamaño del mercado (año base)	USD 63.58 Million
Tamaño del mercado (año de pronóstico)	USD 102.78 Million
Tasa de crecimiento anual compuesta (CAGR)	6.90 %
Jugadoras de los principales mercados	Stanford Health Care (Estados Unidos) HOSPIRA (Ahora parte de Pfizer) (Estados Unidos) Aurora Health Care (Estados Unidos) Takeda Pharmaceutical Company Limited (Japón) Fresenius Kabi AG (Alemania)

Centro de Tratamiento de la Farmacéutica y de la Farmacéutica (Cátedra de Atención Primaria de Salud)

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)Tamaño

El tamaño del mercado de tratamiento de Oriente Medio y África Tipo 1 SBS-IF (Síndrome de Tazón corto con falla intestinal) fue valorado en USD 63,58 millones en 2025 y se espera que alcance USD 102,78 millones en 2033, en una CAGR de 6,9% durante el período de previsión. El mercado está presenciando un crecimiento constante debido a la creciente prevalencia del síndrome de intestino corto asociado con insuficiencia intestinal, la creciente conciencia de los trastornos gastrointestinales raros y los avances continuos en terapias nutricionales y farmacológicas especializadas. La creciente adopción de enfoques multidisciplinarios de tratamiento, junto con mejores capacidades de diagnóstico y mejores estrategias de gestión de pacientes, está apoyando aún más la expansión del mercado.

La creciente carga de las reseecciones intestinales como la enfermedad de Crohn, la isquemia mesentérica, el trauma, las anomalías congénitas y las cirugías relacionadas con el cáncer ha contribuido significativamente a la demanda de tratamientos tipo 1 SBS-IF. Los proveedores de atención médica están utilizando cada vez más la nutrición parenteral, el apoyo nutricional entral y las terapias analógicas del péptido-2 (GLP-2) para mejorar la adaptación intestinal, reducir las complicaciones y mejorar la calidad de vida del paciente.

Principales tendencias del mercado "Análisis

Arabia Saudita dominaba el Medio Oriente y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) Mercado de tratamiento con la mayor cuota de ingresos del 19,42% en 2025, respaldada por infraestructuras sanitarias avanzadas, políticas de reembolso sólidas y acceso generalizado a centros de rehabilitación intestinal especializados.
El segmento de la Terapia de Apoyo Nutricional llevó al mercado con una cuota de 41,73% en 2025, impulsada por su papel crítico en el mantenimiento de la hidratación, la absorción de nutrientes y la gestión general del paciente durante la recuperación intestinal.
Se espera que los Emiratos Árabes Unidos sean el país de más rápido crecimiento en un CAGR de 7,5% entre 2026 y 2033, alimentado por la mejora de la accesibilidad de la salud, el aumento de la conciencia de los trastornos gastrointestinales raros y la creciente inversión en opciones de tratamiento avanzadas en las economías emergentes.
Las terapias emergentes y avanzadas son el segmento de la modalidad de tratamiento más rápido, proyectado para registrar un CAGR del 7,2%, lo que refleja una creciente adopción de biológicos innovadores, análogos GLP-2 y enfoques de tratamiento regenerativo dirigidos a reducir la dependencia de nutrición parenteral a largo plazo.
El segmento Core SBS-IF Market domina la categoría de atribución del mercado con una cuota de ingresos del 56,80% en 2025, apoyada por la población paciente sustancial que requiere una gestión de falla intestinal especializada y continua.
El segmento de fase aguda (Tipo 1 SBS-IF) representó la mayor parte del 48,29% en 2025, impulsado por la necesidad inmediata de apoyo nutritivo intensivo, manejo de fluidos e intervención clínica después de la resección o lesión intestinal principal.
Se prevé que el segmento de fase de adaptación sea la categoría de fase de mayor crecimiento, registrando un CAGR del 7,1% durante el período de previsión, debido a la creciente concentración en terapias que mejoran la adaptación intestinal, mejoran la absorción de nutrientes y apoyan la recuperación de pacientes a largo plazo.

Tamaño del mercado

Medio Oriente y Valor del Mercado de África (2025): 63,58 millones de dólares
Valor de mercado esperado (2033): 102,78 millones de dólares
CAGR prefabricado (2026–2033): 6,9%
País de cultivo más rápido: Emiratos Árabes Unidos

Ámbito de presentación de informesTipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Atributos	Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)Market Insights
Segmentos cubiertos	Por Modalidad de Tratamiento:Terapia de Apoyo Nutricional, Terapia Farmacológica, Tratamiento Intervencional Quirúrgico y Terapias Avanzadas Emergentes Por Atribución al Mercado:Core SBS-IF Market, SBS-IF Atributable Market, y Adjacent / Non-Specific Market Por fase de gestión de enfermedades:fase aguda (Tipo 1 SBS-IF), fase de adaptación y fase de recuperación Por tipo de paciente:Adulto y Pediatría Por Ruta de Administración:Intravenosa, Subcutánea, Oral y Enteral Por tipo intravenoso:PN e inyectables Por Usuario Final:Hospitales (Acute Care), Home Care (HPN Programs), ICU Settings, Specialty GI Centers y Pediatric Specialty Hospitals Por Canal de Distribución:Farmacia Hospitalaria, Farmacia Especial, Farmacia Retail, y Farmacia Online
Países cubiertos	Oriente Medio y África Arabia Saudita · Sudáfrica Egipto Israel · Emiratos Árabes Unidos · Kuwait Omán Qatar · Bahrein · El resto del Oriente Medio y África
Principales jugadores del mercado	· Stanford Health Care (U.S.) · Nestle Health Science (Suiza) · HOSPIRA (Ahora parte de Pfizer) (U.S.) · Cuidado de Salud Aurora (EE.UU.) · Takeda Pharmaceutical Company Limited (Japón) · Fresenius Kabi AG (Alemania) · Grifols (España) · Laboratorios Abbott (U.S.) · Shandong Qidu Pharmaceutical Co., Ltd. (China) · Ferring Pharmaceuticals (Suiza) · Salud UF (EE.UU.) · Baxter International INC (U.S.) · VectivBio AG (Suiza) · Hikma Pharmaceuticals PLC (Reino Unido) · NUTRICIA (DANONE) (Países Bajos) · Amsino International, Inc. (U.S.) · Braun Melsungen AG (Alemania) · ContinuumRx (U.S.) · JEDUX PARENTERAL PRIVATE LIMITED (India) · Beverly Hills Digestive Care (U.S.) · Elección de la Nutrición Parenteral LLC (U.S.) · Sistemas Integrados de Atención (U.S.) · Camvitaa (India) · Regenesis de Eclipse (U.S.) · LABORATOIRE DIELEN (Francia) · Vision Parenteral Pvt. Ltd. (India) · Atención de la salud aguda (India) · Nutrego (Polonia) · Pharmko, Inc. (U.S.) · Soluciones de infusión (U.S.) · Salud UF (EE.UU.) · Sistemas Integrados de Atención (U.S.) · Elección de la Nutrición Parenteral LLC (U.S.) · ContinuumRx (U.S.) · NUTRICIA NORTH AMERICA (U.S.) · Terapéutica Napo (U.S.) · una empresa Moog (U.S.) · ICU Medical, Inc. (U.S.) · Regenesis de Eclipse (U.S.) · Puerto Life Sciences Pvt. Ltd (India) · Bausch Health Companies (Canadá)
Oportunidades de mercado	· Avances en Medicina Regenerativa · Ampliación de la atención nutricional en el hogar
Valor añadido Data Infosets	Además de las ideas sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado comisariados por Data Bridge Market Research también incluyen análisis profundos de expertos, epidemiología de pacientes, análisis de tuberías, análisis de precios y marco regulatorio.

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Tendencia: Manejo multidisciplinario complejo de pacientes

Los avances en la medicina regenerativa y la rehabilitación intestinal están creando fuertes oportunidades de crecimiento para el mercado de tratamiento de Oriente Medio y África Tipo 1 SBS-IF. Los investigadores y las instituciones sanitarias se centran cada vez más en terapias que pueden mejorar la adaptación intestinal, regenerar el tejido intestinal dañado y reducir la dependencia a largo plazo de la nutrición parenteral. Según estudios apoyados por los Institutos Nacionales de Salud, enfoques regenerativos como terapia de células madre, ingeniería de tejidos e investigación de trasplantes intestinales están mostrando resultados prometedores para mejorar la absorción de nutrientes y restaurar la función intestinal en pacientes SBS-IF severos. Varios hospitales académicos y centros especializados de rehabilitación intestinal en América del Norte y Oriente Medio y África también están ampliando programas multidisciplinarios de tratamiento que combinan terapias GLP-2, apoyo nutricional avanzado, cirugía y planes de rehabilitación personalizados. Estos desarrollos están ayudando a mejorar la supervivencia del paciente y la calidad de vida a la vez que se abren nuevas oportunidades de tratamiento a largo plazo más allá de la gestión nutricional tradicional.

Medio Oriente y África Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento Dinámica del mercado

Conductor del mercado clave: aumento del SBS-Si la población del paciente

La creciente población paciente que sufre de síndrome de intestino corto con falla intestinal (SBS-IF) se está convirtiendo en uno de los principales factores de crecimiento para el mercado de tratamiento de Oriente Medio y África tipo 1 SBS-IF. SBS-IF se desarrolla principalmente cuando una gran parte del intestino delgado se elimina a través de la cirugía, reduciendo la capacidad del cuerpo para absorber nutrientes y líquidos adecuadamente. Según el National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), la afección ocurre más comúnmente después de pequeñas cirugías de resección intestinal realizadas para enfermedades como la enfermedad de Crohn, cánceres intestinales, traumatismo, obstrucción intestinal, isquemia y trastornos intestinales congénitos. La creciente incidencia de enfermedades inflamatorias intestinales, especialmente la enfermedad de Crohn, contribuye significativamente al aumento de las cirugías intestinales en todo el mundo. NIDDK también afirma que los pacientes con enfermedad severa de Crohn a menudo requieren reseecciones de intestino repetidas, lo que aumenta el riesgo a largo plazo de desarrollar SBS-IF.

Restricción clave / desafío: alto costo de SBS-Si el tratamiento

El alto costo del tratamiento SBS-IF sigue siendo una de las mayores restricciones para el mercado de tratamiento de Oriente Medio y África tipo 1 SBS-IF. pacientes con síndrome de intestino corto con insuficiencia intestinal a menudo requieren nutrición parenteral permanente, monitoreo hospitalario frecuente, rehabilitación intestinal especializada y terapias biológicas avanzadas como teduglutida. Según la información de tratamiento de EE.UU. Food and Drug Administration y Takeda, las terapias GLP-2 como GATTEX pueden costar casi USD 400.000–USD 500.000 al año por paciente en los Estados Unidos, haciendo que el tratamiento sea financieramente difícil para muchas familias y sistemas de salud. Además de los costos de los fármacos, los pacientes con SBS-IF a menudo necesitan atención central de catéter venoso, suplementos nutricionales, pruebas regulares de sangre y reincidencias hospitalarias debido a infecciones o complicaciones de deshidratación. Estos gastos médicos a largo plazo suponen una carga importante tanto para los pacientes como para los proveedores de seguros, especialmente en los países donde la cobertura de reembolso por enfermedades raras sigue siendo limitada.

Oportunidad del mercado clave: Ampliación de terapias biológicas avanzadas y analógicas GLP-2

El mercado de tratamiento de Oriente Medio y África Tipo 1 SBS-IF presenta importantes oportunidades de crecimiento impulsadas por avances continuos en enfoques de gestión terapéutica y nutricional. Aumentar la adopción de nuevas tecnologías biológicas, en particular las terapias analógicas GLP-2, está creando nuevas vías para mejorar la adaptación intestinal y reducir la dependencia de la nutrición parenteral. El enfoque cada vez mayor en los planes de nutrición personalizados y la atención multidisciplinaria es mejorar los resultados de los pacientes y ampliar la accesibilidad al tratamiento. Las economías emergentes ofrecen un potencial considerable debido a la mejora de la infraestructura sanitaria, una mayor conciencia de los trastornos gastrointestinales raros y el aumento del gasto sanitario. Además, la investigación en curso en medicina regenerativa, terapias basadas en células madre e ingeniería de tejido intestinal puede transformar futuros paradigmas de tratamiento. También se espera que la ampliación de los modelos de atención en el hogar y las soluciones de control remoto mejoren la gestión de enfermedades a largo plazo y la calidad de vida de los pacientes

Medio Oriente y África Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

El mercado se segmenta sobre la base de la modalidad de tratamiento, atribución al mercado, fase de gestión de enfermedades, tipo de paciente, vía de administración, tipo intravenoso, usuario final y canal de distribución.

Por Modalidad de Tratamiento

Sobre la base de la modalidad de tratamiento, el Oriente Medio y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) El mercado de tratamiento se segmenta en terapia de apoyo nutricional, terapia farmacológica, tratamiento intervencional quirúrgico y terapias avanzadas emergentes. El segmento de terapia de apoyo nutricional dominó la mayor cuota de ingresos del mercado de 41,73% en 2025, impulsada por la creciente dependencia de la nutrición parenteral y enteral para la gestión SBS-IF a largo plazo en hospitales y entornos de salud en el hogar. El aumento de la adopción de los programas de nutrición parenteral (HPN), los avances en las formulaciones clínicas de nutrición y el creciente enfoque en la mejora de la calidad de vida del paciente continúan apoyando el crecimiento del segmento. La creciente prevalencia de cirugías gastrointestinales y trastornos intestinales crónicas acelera aún más la demanda de terapias de rehabilitación nutricional. La mejora del apoyo a los reembolsos y el aumento de la concienciación respecto de la gestión crónica de las fallas intestinales también contribuyen a una adopción más elevada de segmentos en todo el Oriente Medio y África.

Se prevé que el segmento de terapias avanzadas emergentes sea testigo de la CAGR más rápida del 7,2% de 2026 a 2033, alimentada por la creciente adopción de biológicas, terapias analógicas GLP-2 y enfoques innovadores de rehabilitación intestinal. Aumentar las actividades de investigación centradas en enfermedades gastrointestinales raras y aumentar las inversiones en desarrollo avanzado del tratamiento SBS-IF están expandiendo el paisaje terapéutico. Las empresas farmacéuticas se centran cada vez más en la medicina de precisión y terapias orientadas para reducir la dependencia de la nutrición parenteral y mejorar la función intestinal. Los marcos regulatorios de apoyo, la expansión de ensayos clínicos y los avances en soluciones de tratamiento personalizadas contribuyen aún más al rápido crecimiento de segmentos en todo el mercado de tratamiento del tipo 1 SBS-IF.

By Market Attribution

Sobre la base de la atribución del mercado, el Oriente Medio y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) El mercado de tratamiento se segmenta en el mercado central SBS-IF, mercado atribuible SBS-IF y mercado adyacente / no específico. El segmento central del mercado SBS-IF dominó la mayor cuota de ingresos del mercado de 56,80% en 2025, impulsada por el creciente diagnóstico de casos de insuficiencia intestinal que requieren apoyo nutricional especializado y gestión clínica a largo plazo. La creciente adopción de terapias de nutrición parenteral, el aumento de la conciencia sobre los trastornos intestinales crónicos y la ampliación del acceso a centros de tratamiento gastrointestinales especializados continúan apoyando el crecimiento del segmento. El aumento del gasto sanitario en enfermedades gastrointestinales raras y los avances en los programas de rehabilitación nutricional están acelerando aún más la demanda del mercado. La mejora de las políticas de reembolso y la creciente integración de las soluciones de atención de la salud en el hogar también contribuyen a una fuerte adopción de segmentos en todo el Oriente Medio y África.

Se prevé que el segmento de mercado atribuible SBS-IF sea testigo de la CAGR más rápida del 7,1% de 2026 a 2033, alimentada por el creciente reconocimiento de complicaciones relacionadas con SBS-IF y la creciente necesidad de intervenciones terapéuticas de apoyo. La creciente prevalencia de cirugías gastrointestinales, resecciones intestinales y trastornos digestivos crónicos está impulsando la demanda de soluciones de tratamiento atribuibles y programas de atención nutricional asociados. Los proveedores de atención médica se centran cada vez más en la gestión temprana de las enfermedades y en enfoques multidisciplinarios de tratamiento para mejorar los resultados de los pacientes. Los avances continuos en terapias biológicas, apoyo nutricional clínico y tecnologías de monitoreo de pacientes están contribuyendo aún más a la expansión de segmentos. Se espera que el aumento de las inversiones en la infraestructura de tratamiento de enfermedades raras y las iniciativas gubernamentales de apoyo impulsen un crecimiento rápido en todo el Oriente Medio y el mercado de tratamiento del tipo 1 SBS-IF de África.

Por fase de gestión de enfermedades

Sobre la base de la fase de gestión de enfermedades, el Mercado de Tratamiento de Oriente Medio y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) se segmenta en fase aguda (Tipo 1 SBS-IF), fase de adaptación y fase de recuperación. El segmento de fase aguda (Tipo 1 SBS-IF) dominó la mayor cuota de ingresos del mercado de 48,29% en 2025, impulsada por el creciente número de pacientes que requieren intervención nutricional inmediata y manejo clínico intensivo tras cirugías intestinales y complicaciones gastrointestinales graves. El aumento de la dependencia del apoyo a la nutrición parenteral, el aumento de las tasas de hospitalización y la creciente demanda de atención gastrointestinal especializada siguen apoyando el crecimiento de los segmentos. Los avances en programas intensivos de terapia nutricional y mejores tecnologías de monitoreo están mejorando aún más los resultados del tratamiento. El aumento de la conciencia sobre el diagnóstico y la gestión tempranos del SBS-IF también contribuye a una fuerte adopción de segmentos en Oriente Medio y África.

Se prevé que la fase de adaptación sea testigo de la CAGR más rápida del 7,1% entre 2026 y 2033, impulsada por el creciente enfoque en la rehabilitación intestinal y las estrategias de optimización nutricional a largo plazo. Aumentar la adopción de terapias biológicas, programas de nutrición personalizados y enfoques avanzados de rehabilitación está apoyando una mejor adaptación intestinal y una menor dependencia de la nutrición parenteral. Los proveedores de atención médica están haciendo cada vez más hincapié en los modelos multidisciplinarios de tratamiento para mejorar la recuperación de pacientes y la calidad de vida. Los avances continuos en las formulaciones clínicas de nutrición y soluciones de gestión de la salud en el hogar contribuyen aún más a la expansión de segmentos. Se espera que el aumento de las inversiones en infraestructuras de rehabilitación gastrointestinales y las innovaciones de tratamiento de apoyo impulsen un rápido crecimiento en todo el Oriente Medio y el mercado de tratamiento del tipo 1 de África SBS-IF.

Por tipo de paciente

Sobre la base del tipo de paciente, el Mercado de Tratamiento de Oriente Medio y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) se segmenta en adulto y pediatría. El segmento adulto dominó la mayor cuota de ingresos del mercado de 71,62% en 2025, impulsada por la creciente prevalencia de trastornos gastrointestinales, resección intestinal y complicaciones digestivas crónicas entre la población adulta. Aumentar la dependencia de las terapias de nutrición parenteral a largo plazo, aumentar las tasas de hospitalización y la adopción creciente de programas de apoyo nutricional a la salud doméstica continúan apoyando el crecimiento del segmento. Los avances en las formulaciones nutricionales y los enfoques de atención gastrointestinales integrados están mejorando aún más los resultados del tratamiento. El aumento de la conciencia sobre la gestión crónica de las fallas intestinales y los marcos de reembolso de apoyo también están contribuyendo a una fuerte adopción de segmentos en todo el Oriente Medio y África.

Se prevé que el segmento pediátrico sea testigo de la CAGR más rápida del 7,1% entre 2026 y 2033, alimentada por la creciente incidencia de trastornos intestinales congénitos, complicaciones gastrointestinales neonatales y casos de insuficiencia intestinal pediátrica. Aumentar el enfoque en terapias especializadas de apoyo nutricional pediátrico y programas avanzados de rehabilitación intestinal está impulsando la expansión del segmento. Los proveedores de atención médica están adoptando cada vez más estrategias de tratamiento personalizadas y modelos multidisciplinarios de atención para mejorar los resultados de los pacientes pediátricos a largo plazo. Los avances continuos en las formulaciones de nutrición parenteral pediátrica y las soluciones de asistencia a domicilio contribuyen aún más al crecimiento del mercado. Se espera que el aumento de las inversiones en infraestructuras de tratamiento gastrointestinales pediátricas y el aumento de la conciencia acerca de las estrategias de intervención temprana aceleren la demanda de segmentos en todo el mercado de tratamiento del tipo 1 SBS-IF.

Por Ruta de Administración

Sobre la base de la ruta de la administración, Oriente Medio y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) El mercado de tratamiento se segmenta en intravenosa, subcutánea, oral y enteral. El segmento intravenoso dominaba la mayor cuota de ingresos del mercado del 49,61% en 2025, impulsada por la creciente dependencia de las terapias de nutrición parenteral para la gestión inmediata y a largo plazo de SBS-IF. La administración intravenosa sigue siendo esencial para los pacientes con graves limitaciones de absorción intestinal y deficiencias nutricionales agudas. El aumento de la adopción de programas de nutrición parenteral (HPN), los avances en las tecnologías de la infusión y la creciente disponibilidad de formulaciones nutricionales especializadas continúan apoyando el crecimiento del segmento. El aumento de las tasas de hospitalización relacionadas con los trastornos gastrointestinales y los marcos de reembolso de apoyo están contribuyendo aún más a una fuerte adopción de segmentos en todo el Oriente Medio y África.

Se prevé que el segmento subcutáneo será testigo de la CAGR más rápida del 7,2% entre 2026 y 2033, alimentada por la creciente adopción de terapias biológicas y opciones avanzadas de tratamiento inyectable para la gestión SBS-IF. Aumentar la preferencia por métodos de entrega de drogas mínimamente invasivos, mejorar la comodidad de los pacientes y reducir la dependencia hospitalaria están impulsando la expansión del segmento. Los proveedores de atención de la salud utilizan cada vez más la administración subcutánea para terapias específicas y enfoques de gestión de enfermedades a largo plazo. Los avances continuos en las formulaciones biológicas, los dispositivos de autoadministración y los programas de tratamiento de la atención en el hogar contribuyen aún más al crecimiento del mercado. Se espera que el aumento de las inversiones en terapias gastrointestinales innovadoras y el aumento de la conciencia sobre soluciones de tratamiento centradas en el paciente aceleren la demanda de segmentos en el Medio Oriente y el Mercado de Tratamiento del SBS-IF de África.

Por Usuario final

Sobre la base del usuario final, el Mercado de Tratamiento de Oriente Medio y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) se segmenta en hospitales (cuidado agudo), atención domiciliaria (programas de HPN), configuración de UCI, centros especiales de GI y hospitales de especialidades pediátricas. El segmento de hospitales (cuidado agudo) dominó la mayor parte de ingresos del mercado del 38,59% en 2025, impulsada por las crecientes tasas de hospitalización asociadas con insuficiencia intestinal, cirugías gastrointestinales y graves deficiencias nutricionales. Los hospitales siguen siendo la configuración primaria de tratamiento para el apoyo nutricional intensivo, la gestión aguda del SBS-IF y la atención gastrointestinal multidisciplinar. El aumento de la adopción de terapias de nutrición parenteral avanzadas, el aumento de la disponibilidad de equipos de atención especializada y la creciente inversión en programas de rehabilitación nutricional basados en hospitales siguen apoyando el crecimiento del segmento. Las estructuras de reembolso de apoyo y la mejora de la infraestructura clínica contribuyen aún más a una fuerte adopción de segmentos en todo el Oriente Medio y África.

Se prevé que el segmento de atención (programas de HPN) sea testigo de la CAGR más rápida del 7,4% de 2026 a 2033, alimentada por la creciente adopción de soluciones de nutrición parenteral para la gestión SBS-IF a largo plazo. Aumentar la preferencia por los enfoques de tratamiento basados en el hogar, mejorar la comodidad de los pacientes y reducir los costos de hospitalización están impulsando la expansión del segmento. Los proveedores de atención de salud están enfatizando cada vez más los programas de atención de salud para mejorar la calidad de vida y los resultados de gestión nutricional a largo plazo. Los avances continuos en sistemas de infusión portátiles, tecnologías de monitoreo remoto de pacientes y terapias nutricionales personalizadas están contribuyendo aún más al crecimiento del mercado. Se espera que el aumento de la conciencia sobre la gestión crónica de fallos intestinales y la ampliación de la infraestructura de atención de la salud en el hogar aceleren la demanda de segmentos en todo el Oriente Medio y el mercado de tratamiento del tipo 1 SBS-IF de África.

Por canal de distribución

Sobre la base del canal de distribución, el Medio Oriente y África Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) El mercado de tratamiento se segmenta en farmacia hospitalaria, farmacia especializada, farmacia minorista y farmacia en línea. El segmento de farmacia hospitalaria dominó la mayor cuota de ingresos del mercado de 46,62% en 2025, impulsada por las crecientes tasas de hospitalización asociadas con el fracaso intestinal y la creciente administración de terapias de nutrición parenteral en entornos de atención aguda. Las farmacias hospitalarias siguen siendo los canales de distribución primaria para formulaciones nutricionales especializadas, terapias biológicas y productos intensivos de tratamiento SBS-IF. La creciente disponibilidad de programas multidisciplinarios de atención gastrointestinal y la creciente demanda de soluciones de tratamiento supervisadas clínicamente continúan apoyando el crecimiento del segmento. Los marcos de reembolso de apoyo y la ampliación de la infraestructura hospitalaria contribuyen aún más a una fuerte adopción de segmentos en todo el Oriente Medio y África.

Se prevé que el segmento de farmacias especializadas sea testigo de la CAGR más rápida del 7,2% entre 2026 y 2033, alimentada por la creciente demanda de terapias biológicas avanzadas, formulaciones nutricionales personalizadas y soluciones de tratamiento SBS-IF a largo plazo. La creciente preferencia por los servicios especializados de apoyo farmacéutico y el mejor acceso a los productos de tratamiento de enfermedades raras están impulsando la expansión de segmentos. Los proveedores de atención de salud están colaborando cada vez más con las farmacias especializadas para garantizar el seguimiento continuo de pacientes, la gestión de terapia y el apoyo al tratamiento basado en el hogar. Los avances continuos en las redes de distribución de drogas especializadas y los programas de asistencia a los pacientes contribuyen aún más al crecimiento del mercado. Se espera que el aumento de la conciencia sobre la gestión crónica de fallas intestinales y la adopción creciente de enfoques de tratamiento centrados en el paciente aceleren la demanda de segmentos en todo el Oriente Medio y el mercado de tratamiento del tipo 1 SBS-IF de África.

Medio Oriente y África Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Arabia Saudita dominaba el Mercado de Tratamiento de Oriente Medio Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal), lo que representaba la mayor proporción de ingresos del 19,42% en 2025. La posición principal del país está respaldada por su infraestructura sanitaria bien desarrollada, aumentando las tasas de diagnóstico de trastornos gastrointestinales raros, y un fuerte acceso a terapias de nutrición parental avanzadas y centros de tratamiento especializados. El aumento del gasto sanitario, las iniciativas gubernamentales para mejorar la gestión de las enfermedades raras y la presencia de los principales hospitales equipados con equipos multidisciplinarios de atención han contribuido aún más al crecimiento del mercado. Además, la creciente conciencia entre los profesionales de la salud y los pacientes con respecto a las opciones de tratamiento SBS-IF sigue impulsando la demanda en toda Arabia Saudita.

Sudáfrica Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Se proyecta que el mercado de tratamiento U.K. Tipo 1 SBS-IF (síndrome del intestino delgado con falla intestinal) se expanda en un CAGR sustancial durante todo el período de pronóstico, impulsado por aumentar la conciencia sobre la gestión de falla intestinal crónica, la adopción creciente de terapias avanzadas de apoyo nutricional, y la creciente inversión sanitaria en enfermedades gastrointestinales raras. El aumento de la demanda de programas de nutrición parental basados en el hogar, la ampliación de los enfoques multidisciplinarios de atención y el creciente uso de soluciones de tratamiento biológico están apoyando el crecimiento del mercado. Además, las políticas de asistencia sanitaria de apoyo y la presencia de infraestructuras clínicas avanzadas de nutrición están acelerando aún más la adopción de soluciones de tratamiento SBS-IF en hospitales y centros de atención especializada.

Egipto tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Se espera que el Mercado de Tratamiento Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) presenciará un crecimiento significativo durante el período de pronóstico, impulsado por la creciente prevalencia de trastornos gastrointestinales, la adopción creciente de terapias clínicas de nutrición y el enfoque creciente en programas de rehabilitación intestinal a largo plazo. Ampliar las inversiones en infraestructura sanitaria, aumentar el uso de formulaciones avanzadas de nutrición parenteral y concienciar cada vez más acerca de enfoques centrados en los pacientes de gestión SBS-IF están contribuyendo a la expansión del mercado. Además, los marcos de reembolso de apoyo y el aumento de la disponibilidad de instalaciones especializadas de tratamiento gastrointestinales están fomentando la adopción de soluciones de tratamiento SBS-IF en los entornos hospitalarios y de atención a domicilio.

Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

El tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento La industria del mercado está dirigida principalmente por empresas bien establecidas, incluyendo:

Nestle Health Science (Suiza)

Stanford Health Care (Estados Unidos)
HOSPIRA (Ahora parte de Pfizer) (Estados Unidos)
Aurora Health Care (U.S.)
Takeda Pharmaceutical Company Limited (Japón)
Fresenius Kabi AG (Alemania)
Grifols (España)
Abbott Laboratories (U.S.)
Shandong Qidu Pharmaceutical Co., Ltd. (China)
Ferring Pharmaceuticals (Suiza)
UF Health (Estados Unidos)
Baxter International INC (U.S.)
VectivBio AG (Suiza)
Hikma Pharmaceuticals PLC (Reino Unido)
NUTRICIA (DANONE) (Países Bajos)
Amsino International, Inc. (U.S.)
Braun Melsungen AG (Alemania)
ContinuumRx (U.S.)
JEDUX PARENTERAL PRIVATE LIMITED (India)
Beverly Hills Digestive Care (Estados Unidos)
Elección de la Nutrición Parenteral LLC (U.S.)
Integrated Care Systems (U.S.)
Camvitaa (India)
Eclipse Regenesis (U.S.)
LABORATOIRE DIELEN (Francia)
Vision Parenteral Pvt. Ltd. (India)
Aculife Healthcare (India)
Nutrego (Polonia)
Pharmko, Inc. (U.S.)
Infusion Solutions (U.S.)
UF Health (Estados Unidos)
Integrated Care Systems (U.S.)
Elección de la Nutrición Parenteral LLC (U.S.)
ContinuumRx (U.S.)
NUTRICIA NORTH AMERICA (Estados Unidos)
Terapéutica Napo (U.S.)
a Moog company (Estados Unidos)
ICU Medical, Inc. (Estados Unidos)
Eclipse Regenesis (U.S.)
Puerto Life Sciences Pvt. Ltd (India)
Bausch Health Companies (Canadá)

Los últimos desarrollos en Oriente Medio y África Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

En enero de 2026, Fresenius Kabi ha introducido una nueva forma de dosificación de su ustekinumab biosimilar (Otulfi), que ofrece un vial de dosis única de 45 mg/0,5 mL. Esta adición amplía el rango de presentación disponible de Otulfi, que es un biosimilar a Stelara de Janssen (ustekinumab). Con esta actualización, Fresenius Kabi proporciona ahora múltiples formas de dosis y fortalezas del producto de referencia, mejorando la flexibilidad para los médicos y opciones de tratamiento para los pacientes. Esto fortalece la cartera biosimilar de Fresenius Kabi mejorando la flexibilidad del producto.
En marzo de 2025, Baxter International ha introducido el IV Verify Line Labeling System, una solución automatizada diseñada para reemplazar etiquetas IV manuscritas con etiquetado estandarizado y basado en códigos de barras en hospitales. El sistema ayuda a los clínicos a imprimir etiquetas adhesivas claras y codificadas por colores para el tubo IV, mejorando la precisión y reduciendo errores de medicamentos en la parte posterior. Fortalece la posición de Baxter en la tecnología de infusión hospitalaria.e
En febrero de 2026, Nestlé Health Science anunció la inclusión de sus productos nutricionales en un marco de reembolso excepcional dentro del sistema de salud pública de Portugal, permitiendo que los productos elegibles sean cubiertos parcialmente o totalmente por el Servicio Nacional de Salud. Esta decisión regulatoria refuerza el acceso de los pacientes a soluciones de nutrición clínica y apoya la integración de la nutrición médica en vías formales de reembolso de salud. Esto beneficiará a la empresa mejorando la accesibilidad de los productos, ampliando la demanda basada en recetas y reforzando su posición dentro del mercado clínico de nutrición reembolsado.

SKU-76250

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Click on image to enlarge

Panel de análisis de datos interactivo
Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
Acceso de analista de investigación para personalización y consultas
Análisis de la competencia con panel interactivo
Últimas noticias, actualizaciones y análisis de tendencias
Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia

Solicitud de demostración

Tabla de contenido

1 INTRODUCCIÓN

1.1 OBJETIVOS DEL ESTUDIO

1.2 DEFINICIÓN DEL MERCADO

1.3 Examen general de los niveles medio y aFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITACIONES

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 ÁMBIÉN GEOGRÁFICO

2.3 AÑOS ESTUDIOS PARA EL ESTUDIO

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 ENTREVISTAS PRIMARÍAS CON LEADRES DE OPINION KEY

2.6 GRID DE POSICIÓN DEL MERCADO

2.7 VENDOR SHARE ANALISIS

2.8 MULTIVARIATE MODELING

2.9 CURVE DE TIPO DE PRODUCTOS

2.1 MARKET APPLICATION GRID

2.11 FUERZAS SEGUNDARIAS

2.12 ASUNTOS

RESUMEN EJECUTIVO

4 fotos INSIGHTS

4.1 ANÁLISIS PESTEL

4.1.1 INTRODUCCIÓN

4.1.2 ANÁLISIS POLÍTICO

4.1.3 ANÁLISIS ECONÓMICO

4.1.4 ANÁLISIS SOCIAL

4.1.5 ANÁLISIS TECNOLOGICO

4.1.6 ANÁLISIS AMBIENTE

4.1.7 ANÁLISIS JURÍDICO

4.1.8 CONCLUSIÓN

4.2 FIVE FORCES DE PORTER

4.2.1 INTRODUCCIÓN

4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)

4.2.3 POWER BARGAINING POWER OF BUYERS – ALTO

4.2.4 Tres de los nuevos territorios - MODERATE

4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE

4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE

4.2.7

4.3 QUADRANT DE EVALUACIÓN DE EMPRESAS

4.4 METODOLOGÍA DEL FONDO PACTO (MODEL DE MANDATORIA)

4.4.1 Un FONDO PACIENTE DE BOTTOM-UP será CONSTRUCIDO

4.4.1.1 POBLACIÓN TOTAL DE SBS

4.4.1.2 POBLACIÓN SBS-IF

4.4.1.3 DIAGNOSED SBS-IF PATIENTS

4.4.1.4 PACIENTES TREATED SBS-IF

4.4.1.5 POOLAS PACIENTES THERAPY-SPECIFIC

4.4.1.6 ESTE ENSURES PATIENT NUMBERS are DIRECTLY ESTIMATED, NO INFERREDED from MARKET SIZE

4.4.1.7 MIDDLE EAST AND AFRICA PATIENT FUNNEL SEGMENTATION

4.4.1.8 POBLACIÓN TOTAL DE SBS

4.4.1.9 SBS ADULT

4.4.1.10 PEDIATRIC SBS

4.4.1.11 POBLACIÓN SBS-IF

4.4.1.12 TYPE 1 SBS-IF (ACUTE)

4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)

4.4.1.14 TYPE 3 SBS-IF (CHRONIC)

4.4.1.15 POBLACIÓN DIAGNOSADA

4.4.1.16 DIAGNOSED – HOSPITAL-BASED

4.4.1.17 DIAGNOSED – OUTPATIENT

4.4.1.18 UNDIAGNOSED / MISCLASSIFIED

4.4.1.19 POBLACIÓN PACIENTE TREATED

4.4.1.20 PACIENTES TREATEDES

4.4.1.21

4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)

4.4.2.1 POPULACIÓN PACIENTE PN-DEPENDIENTO (SEGMENTO DE CORE)

4.4.2.2 FULLY PN-DEPENDENT

4.4.2.3 PARTIALLY PN-DEPENDENT

4.4.2.4 UCI PN-DEPENDENT (TYPE 1 ACUTE)

4.4.2.5 HOME PN-DEPENDENT

4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS

4.4.2.7 INCLUYEN LOS PACIENTES RECIBIDAS

4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)

4.4.2.9

GLP-2

4.4.2.11 PN-WEANING PATIENTS

4.4.2.12 PEDIATRIC VS ADULT

4.4.2.13 PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)

4.4.2.14 USUARIOS ANTI-DIARRHEAL

4.4.2.15

4.4.2.16 ANTIBIOTIC (SIBO) PACIENTES

4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS

4.4.2.18 PACIENTES SURGICOS Y TRANSPLANTES

4.4.2.19 PROCEDIMIENTOS DE LENGTHENAL

4.4.2.20 PACIENTES TRANSPLANTES

4.4.2.21 SURVIVORS POST-TRANSPLANT

4.4.3 SEGMENTACIÓN PACIENTE POR DEPENDENCY STATUS (HIGHLY IMPORTANT)

POPULACIÓN PN-DEPENDIEN

4.4.3.2 SEGUIMIENTO DE LA REVENCIÓN DE LOS PAÍSES

4.4.3.3 POPULACIÓN DE PNBANING

4.4.3.4 RESPONDERS GLP-2

POPULACIÓN PN-INDEPENDENT

4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY

4.4.4 SEGMENTACIÓN PACIENTE POR FASE DISEÑO (TYPE 1 FOCUS)

4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)

4.4.4.2 ICU-MANAGED PATIENTS

4.4.4.3 HIGH PN UTILIZATION

4.4.4.4 FASE DE ADAPTACIÓN

4.4.4.5 TRANSICIÓN A LA NUTRICIÓN ENTERAL

4.4.4.6 INITIATION OF GLP-2 THERAPY

4.4.4.7 HABILIZACIÓN / ESTABILIZACIÓN

4.4.4.8 REDUCED PN DEPENDENCY

4.4.4.9 MANTENIMIENTO DE LOS TERMINOS

4.4.4.10 SEGMENTACIÓN PACIENTE POR CARE

4.4.4.11 PACIENTES HOSPITAL-BASED

4.4.4.12 UCID

4.4.4.13 WARDS SURGICAS

4.4.4.14 PACIENTES DE CARE

4.4.4.15 HOME PARENTERAL NUTRITION (HPN)

4.4.16 CENTROS ESPECIALES

4.4.4.17 CENTROS INTESTINALES DE REHABILITACIÓN

4.4.5 SEGMENTACIÓN PACIENTE POR LOS DEMOGRAFÍAS

4.4.5.1 GRUPO DE AGE

4.4.5.2 NEONACIONES

4.4.5.3 PEDIATRIC

4.4.5.4

4.4.5.5 GERIATRIC

4.4.5.6 GENDER

4.4.5.7

4.4.5.8 FEMALE

4.4.6 SEGMENTACIÓN PACIENTE POR ETIOLOGÍA

4.4.6.1 ETIOLOGÍA ADULT

4.4.6.2 DISEÑO DE CROHN

4.4.6.3 MESENTERIC ISCHEMIA

4.4.6.4 Respuestas SURGICAS

4.4.6.5 REALIZADO DE LAS NACIONES UNIDAS

4.4.6.6 ETIOLOGÍA PEDIATRIC

4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)

4.4.6.8 DEFECTOS CONGENIALES (ATRESIA, GASTROSCHISIS)

4.4.7 DISTRIBUCIÓN PACIENTE GEOGRÁFICO

4.4.7.1 NORTH AMERICA

4.4.7.2 U.S.

4.4.7.3 CANADA

4.4.7.4 EUROPA

4.4.7.5 ALEMANIA

4.4.7.6

4.4.7.7 Reino Unido

4.4.7.8

4.4.7.9 ESPAÑA

4.4.7.10 ASIA-PAIFIC

4.4.7.11 JAPÓN

4.4.7.12 CHINA

4.4.7.13 INDIA

4.4.8 TREATMENT PENETRATION " UTILIZATION RATES

4.4.8.1 PN PENETRATION RATE

4.4.8.2 % DE PACIENTES SBS-IF EN PN

4.4.8.3 GLP-2

4.4.8.4 % DE LOS PACIENTES ELIGIBLES GLP-2

4.4.8.5 Perfeccionamiento de la Terapia

4.4.8.6 ANTI-DIARRHEAL USAGE RATE

4.4.8.7 PPI USAGE RATE

4.4.8.8 Modificación de los GASTOS PATIENT-LEVEL

4.4.8.9 Gastos anuales

4.4.8.10 PN COST (HOSPITAL VS HOME)

4.4.8.11 GLP-2 THERAPY COST

4.4.8.12 GASTOS DE ARAPACIDAD

4.4.9 COST BY PATIENT TYPE

4.4.9.1 PN-DEPENDENT

4.4.9.2 GLP-2

4.4.9.3

4.4.9.4 DELIVERABLES DELPUT (EXCEL – CLIENT CRITICAL)

4.4.9.5 PACIENTES TOTAL SBS-IF (Por país)

4.4.9.6 VS DIAGNOSED TREATED PATIENTS

4.4.9.7 PN-DEPENDENT PATIENTS

4.4.9.8 GLP-2 TREATED PATIENTS

4.4.9.

4.4.9.10 AVERAGE ANNUAL COST PER THERAPY

4.5 INSIGHTS INDUSTRY

4.5.1 INTRODUCCIÓN

4.5.2 Examen general de la estructura interna

4.5.3 MICRO Y FACTORES ECONÓMICOS MACRO

4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING

4.5.5 ESTRATEGIAS PRINCIPALES

4.5.6 INTERVIEWS with SPECIALISTS

4.5.7 ANÁLISIS Y RECOMENDACIÓN

4.5.8 CONCLUSIÓN

4.6 LA DISRUPCIÓN DE LA GUERRA DE LA GUERRA DE LOS CHAINS PHARMACEUTICAS SUPPLY, GEOGRAPHIC FOOTPRINTs, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES

INTRODUCCIÓN

4.6.2 RESULTIVAMENTE CHAIN

4.6.2.1 DIVERSIFICACIÓN DE LOS SUPLEMENTOS INGRESOS Y PN/DRUG

4.6.2.2 ESTABLECIMIENTO DE LOS HUBES DE PRODUCCIÓN REGIONAL

STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES

4.6.2.4 DESARROLLO DE LAS LOGISTICAS ALTERNATIVAS Y LOS CHAINES COLOS

4.6.2.5 CENTROS ESTRATEGICOS CON CDMOS LEADING (E.G., CATALENT, LONZA)

4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2

4.6.3 ENERGÍA " MANUFACTURING OPERATIONAL COST RISK

4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION ' DRUG FACILITIES

4.6.3.2 GASTOS INCREADOS PARA MATERIALES RAW, EMULSIONES LIPID, Y PHARMACEUTICAS

4.6.3.3 ESTRATEGIAS DE PROCURACIÓN DE LA ENERGÍA ENTRE LOS PN MANUFACTURERES

4.6.3.4 APROBACIÓN DE LAS TECNOLOGÍAS DE MANUFACTURACIÓN DE ENERGÍAS

4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS

4.6.3.6 INTEGRACIÓN DE LA ENERGÍA RENEWABLE EN LAS FACILIDADES DE MANUFACTURACIÓN

4.6.4 Observaciones de la FOOTPRINT GEOGRAPHIC

4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS

4.6.4.2 DIVERSIFICACIÓN DE TEMAS MIDILES Y AFRICA PN/GLP-2 PRODUCCIÓN

4.6.4.3 RELOCACIÓN DE LA PRODUCCIÓN DE KEY INPUT/INTERMEDIATE

4.6.4.4 EXPANSION INTO EMERGING MARKETS with HIGH SBS-IF BURDEN

4.6.4.5 ESTABLECIMIENTO DE LOS HUBOS DE TRANSICIÓN Y DISTRIBUCIÓN REGIONALES

4.6.5 Plantilla SCENARIO " RISK MANAGEMENT

4.6.5.1 DESARROLLO DE PLANES DE CONTINGENCY SUPLEMENTE

4.6.5.2 ESTRATEGIAS DE PROCURACIÓN MULTI-SOURCE PARA PN/GLP-2

4.6.5.3 COLABORACIONES DE GOBIERNO Y SALUD

4.6.5.4 Redes de respuesta de la crisis para las terapias críticas

4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET

4.6.6 CASH " FINANCIERA PROTECCIÓN

4.6.7 RESERVAS DE CAPITAL PARA LA EXPANSIÓN PN " BIOPHARMA

4.6.7.1 DIVERSIFICACIÓN DE LOS PORFOLIOS DE PRODUCTOS Y LAS ESFERAS REVENIDAS

4.6.7.2 INVESTMENTOS EN LA INFRASTRUCTURA DE LA PRODUCCIÓN DOMESTICA

4.6.7.3 INSTITUCIONES DE GOBIERNO Y PARTE PUBLIC-PRIVATE

4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS with HEALTHCARE SYSTEMS

4.6.8 Protección de datos

4.6.8.1 MARCOS DE PROTECCIÓN DE DATOS PARA LOS DATOS CLINICOS Y REALES

4.6.8.2 PROTECCIÓN DE DATOS TRIALES CLINICOS, DATOS PACIENTES Y DESARROLLO DE DROGAS

4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT

4.6.8.4 INTRODUCCIÓN DE LA TERCERA DETECCIÓN DE LA INVESTIGACIÓN Y LAS REDES DE PHARMA

4.6.8.5 CUMPLIMIENTO DE LAS REGULACIONES DE DATOS PHARMACEUTICAS " GXP

4.6.9 NUEVA BUSINESS AND EMERGING REVENUE OPPORTUNITIES " FUTURE OUTLOOK

4.6.10 Conclusión

4.7 EPIDEMIOLOGY

INTRODUCCIÓN

4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER

4.7.3 TREATMENT RATE

4.7.4 MORTALITY RATE

4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL

4.7.6 TREATMENTO DE TRATAMIENTO

4.7.7 Conclusión

4.8 DISTRIBUCIÓN DE PRODUCTOS Y PROYECTOS POR MEDIO DE PEQUEÑA ORIENTE Y MEDIO AFRICA

4.9 DISTRIBUCIÓN DE LOS PROYECTOS DE APROBACIÓN CIENTÍFICA Y FASE - MEDIO EAST Y AFRICA TYPE 1 SBS-IF MARKET

4.1 DISTRIBUCIÓN DE LOS PROYECTOS POR EL ÁREA Y LA FASE THERAPEUTICOS - MEDIO EAST Y AFRICA TYPE 1 SBS-IF MARKET

4.11 ANÁLISIS PIPELINA

INTRODUCCIÓN

4.11.2 TRIALS CLINICAL AND PHASE ANALYSIS

4.11.3 PIPELINA DE DROGAS

4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)

4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)

4.11.6 FASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)

4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)

4.11.8 CONCLUSIÓN

4.12 ANÁLISIS PIPELINA

INTRODUCCIÓN

4.12.2 EMPRESA DE LA PHARMACEUTICA DE TAKEDA – LÍADERSHIP DE LA REGENERACIÓN INTESTINAL

4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION

4.12.4 FRESENIUS KABI AG – LA NUTRICIÓN CLINICA Y EL DESARROLLO DE LA THERAPY INJECTABLE

4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH

4.12.6 LABORATORES ABBOTT – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS

4.12.7

4.13 ANÁLISIS DE THERAPY MARKETED

INTRODUCCIÓN

4.13.2 DRUG/THERAPY

4.13.2.1 MARCO

4.13.2.2 Nombre de los GENERICES

4.13.3 CLASIFICACIÓN PHARMACOLOGICA

4.13.4 INDICACIÓN PRIMARIA

4.13.5 MARKET STATUS

4.13.6 Medios de acción

4.13.7

4.13.8 DISPONIBILIDAD

4.13.9 PACKAGING TYPE

4.13.10 ROUTE OF ADMINISTRATION

4.13.11 FRECUENCIA DE DOS

4.13.12 INSIGHT

4.13 Una visión general de las actividades de desarrollo de la sequía, las miles de carácter reglamentario, la seguridad y la administración, los datos sobre la exclusividad del mercado

4.13.14 FORECAST MARKET OUTLOOK

4.13.14.1 CROSS COMPETITION

4.13.14.2 THERAPEUTIC PORTFOLIO

4.13.14.3 CURRENT DEVELOPMENT SCENARIO

4.13.15

4.14 ANALISIS PIPELINE - ORIENTE MEDIO Y AFRICA TYPE 1 MERCADO DE TRATAMIENTO SBS-IF

4.14.1 TRIALS CLINICAL AND PHASE ANALYSIS

4.14.2 PIPELINA DE DROGAS Y BIOTHERAPY

4.14.3 PHASE III CANDIDATES

4.14.4 PHASE II CANDIDATES

4.14.5 PHASE I CANDIDATES

4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)

4.15 R ' D ANALYSIS

ANÁLISIS COMPARATIVO

4.15.2 LANDSCAPE PARA EL DESARROLLO

4.15.3 INSIGHTS ON REGULATORY MILESTONES

4.15.4 Asistencia técnica

4.15.5 COLABORACIONES Y PARTICIPACIONES DE ASISTENCIA

5 HEALTHCARE TARIFFS IMPACT ANALYSIS

5.1 Examen general

5.2 ESTRUCTURAS DE TARIFF

5.2.1 MUNDIAL EAST AND AFRICA VS. REGIONAL TARIFF STRUCTURES

5.2.2 ESTADOS UNIDOS: MEDICARE/MEDICAID TARIFF POLICIES

5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES

5.2.4 MARKETS EMERGING: TARIFF CHALLENGES FOR NUTRITION " BIOLOGICS

5.2.5 MAJOR MARKET UPTAKE

5.3 TARIFAS PHARMACEUTICAS Y BARRIERS TRADE

5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS

5.3.2 IMPACT ON AFFORDABILITY " ACCESS

5.3.3 ACUERDOS DE COMERCIO DE KEY AFECTANDO PRODUCTOS SBS-IF

5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS

5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES

5.4.2 EFECTO SOBRE LA AFFORDABILIDAD PACIENTE

5.4.3 HABITACIÓN EN EL TOURISMO MEDICAL PARA LAS ARMAS DE SBS-IF

5.5 ACUERDOS DE COMERCIO Y ACTIVIDADES DE SALUD

5.5.1 REGULACIONES DE LA OMC

5.5.2 EJECUCIÓN DE AGUAS COMERCIALES EN EL CAPÍTULO

5.5.3 FTAS IN REDUCING TARIFFS

5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

6 MARKET ACCESS

6.1 10 años de duración

6.2 Subsidios regionales

6.3 APROBACIONES NUEVAS DEL FDA ANUAL PARA LOS TRATAMIENTOS SBS-IF

6.4 MANUFACTURES, DISTRIBUTORS, AND DEALS

6.5 MAJOR MARKET UPTAKE

6.6 PRÁCTICAS DE TRATAMIENTO ACTUAL

6.7 IMPACT OF UPCOMING THERAPIES

7 MARCO REGULATORIO –

7.1 INTRODUCCIÓN

7.2 PROCESO DE APROBACIÓN REGULATORIA

7.3 EASE of REGULATORY APPROVAL

7.4 PATHWAYS DE APROBACIÓN REGULATORIA

7.5 LICENCIA Y REGISTRACIÓN

7.6 POST-MARKEILLANCE

7.7 Guías de buenas prácticas de manipulación

7.8 CONCLUSIÓN

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING SBS-IF PATIENT POPULATION

8.1.2 APROBACIÓN DE LA APROBACIÓN DE LAS ARMAS GLP-2

8.1.3 INCREASING GOVERNMENT " ORPHAN DRUG SUPPORT

8.2 RESTRAINTS

8.2.1 GASTOS DE SBS-IF

8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS

8.3 OPORTUNIDADES

8.3.1 GESTIÓN DE LOS PACIENTES MULTIDISCIPLINARIOS

8.3.2 PROCESOS DE APROBACIÓN REGULATORIA ESTUDIANTE

8.4

8.4.1 AVANCES IN REGENERATIVE MEDICINE

8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE

9 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY

9.1 Examen general

9.2 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

9.2.1 NUTRITIONAL SUPPORT THERAPY

9.2.2 Terapia PHARMACOLOGICA

9.2.3 TREATMENTO SURGICO e INTERVENTIONAL

9.2.4 EMERGING " ADVANCED THERAPIES

9.3 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.3.1 PARENTERAL NUTRITION (PN)

9.3.2 ENTERAL NUTRITION (EN)

9.3.3 PN COMPOSITION

9.4 MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 HOME PARENTERAL NUTRITION (HPN)

9.4.2 LA NUTRICIÓN PARENTERAL PERIPHERAL (PPN)

9.4.3 ADPIC PARENTERAL

9.5 MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 TPN HOSPITAL-BASED

9.5.2 PT PNB

9.6 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

9.6.1 HPN ADULT

9.6.2 PEDIATRIC HPN

9.7 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

9.7.1 HPN LONG-TERM

9.7.2 HPN SHORT-TERM

9.8 MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 FEEDING ORAL

9.8.2 TUBE FEEDING

9.8.3 FORMULA TYPE

9.9 MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.9.1 NASOGASTRIC (NG)

9.9.2 PEG FEEDING

9.9.3 JEJUNOSTOMY FEEDING

9.1 MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.10.1 POLYMERIC

9.10.2 ELEMENTAL

9.10.3 SEMI-ELEMENTAL

9.11 MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.11.1 MACRONUTRIENTS

9.11.2 ELECTROLYTES " FLUIDS

9.11.3 MICRONUTRIENTS

9.12 MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 AMINO ACIDS

9.12.2 EMULSIONES LIPID

9.12.3 DEXTROSE

9.13 MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.13.1 VITAMINS

9.13.2 ELEMENTOS DE TRABAJO

9.14 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.14.1 NORTH AMERICA

9.14.2 EUROPA

9.14.3 ASIA-PACIFIC

9.14.4 ORIENTE MEDIO Y ÁFRICA

9.14.5 SOUTH AMERICA

9.15 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.15.1 Terapia de ADAPTACIÓN HORMONAL

9.15.2 Terapia ANTI-DIARHEAL

9.15.3 ANTI-SECRETORY THERAPY

9.15.4 APLICACIÓN MICRONUTRIENTE

9.15.5 THERAPY ANTI-INFECTIVE

9.15.6 BILE ACID " ABSORPTION MODIFIERS

9.16 MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.16.1 ANÁLOGO GLP-2

9.16.2 GROWTH HORMONE THERAPY

9.16.3 IGF-1 " ANALOGUES

9.17 MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.17.1

9.17.2 APRAGLUTIDE (LATE-STAGE)

9.17.3 ANALOGOS GLP-2 DE CUMPLIMIENTO

9.18 MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

9.18.1 HUMATROPE

9.18.2 NORDITROPIN

9.18.3 GENOTROPIN

9.19 MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.19.1 INCRELEX

9.19.2 OTROS

9.2 MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.20.1 OPIOID-BASED

9.20.2 ORGANIZACIONES NO ORGANIZADAS

9.21 MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.21.1 LOPERAMIDE

9.21.2 CODEINA

9.22 MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.22.1 INHIBITORES DE PUMP PROTON

9.22.2 ANÁLOGOS SOMATOSTATALES

9.22.3 H2 RECEPTOR ANTAGONISTAS

9.23 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.23.1 OMEPRAZOLE

9.23.2 PANTOPRAZOLE

9.23.3 ESOMEPRAZOLE

9.23.4 OTROS

9.24 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

9.24.1 OCTREOTIDE

9.24.2 OTROS

9.25 MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.25.1 FAMOTIDINE

9.25.2 OTROS

9.26 MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.26.1 VITAMINAS FAT-SOLUBLE (A, D, E, K)

9.26.2 ELECTROLYTES

9.26.3 VITAMIN B12

9.26.4 APLICACIÓN MINERAL

9.27 MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.27.1 ANTÍTICOS BROAD-SPECTRUM

9.27.2 THERAPY

9.28 MIDDLE EAST AND AFRICA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.28.1 BILE ACID SEQUESTRANTS

9.28.2 FAT ABSORPTION ENHANCERS

9.29 ASISTENCIAS MUNDIALES DE EAST Y ÁFRICA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

9.29.1

9.29.2 COLESEVELAM

9.29.3 Otros

9.3 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.30.1 NORTH AMERICA

9.30.2 EUROPA

9.30.3 ASIA-PACIFIC

9.30.4 ORIENTE MEDIO Y ÁFRICA

9.30.5 SOUTH AMERICA

9.31 MIDDLE EAST AND AFRICA SURGICAL ' INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.31.1 PROCEDIMIENTOS DE LA LENGTHENAL

9.31.2 OSTOMÍA " RECONSTRUCCIÓN "

9.31.3 TRANSPLANTACIÓN INTESTINAL

9.32 MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.32.1

9.32.2 BIANCHI PROCEDURE

9.33 MIDDLE EAST AND AFRICA OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.33.1

9.33.2 JEJUNOSTOMY

9.33.3 REVERSAL SURGERY

9.34 MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.34.1 CENTRO SMALL ISOLATED

9.34.2 LIVER + INTESTINE

9.34.3 TRANSPLANT MULTIVISCERAL

9.35 MIDDLE EAST AND AFRICA SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.35.1 NORTH AMERICA

9.35.2 EUROPA

9.35.3 ASIA-PACIFIC

9.35.4 ORIENTE MEDIO Y ÁFRICA

9.35.5 SOUTH AMERICA

9,36 MIDDLE EAST AND AFRICA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.36.1 MEDICINA

9.36.2 Terapia de apoyo a la MICROBIOME

9.36.3 GENE THERAPY

9.37 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.37.1

9.37.2 INTESTINA TISSUE-ENGINEERED

9.38 MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.38.1

9.38.2 FMT

9.39 MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.39.1 Inicio de la FUNCIÓN ABSORPTIVE

9.39.2 MUCOSAL GROWTH MODULATION

9.4 MIDDLE EAST AND AFRICA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.40.1 NORTH AMERICA

9.40.2 EUROPA

9.40.3 ASIA-PACIFIC

9.40,4 MIDDLE EAST AND AFRICA

9.40.5 SOUTH AMERICA

10 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION

10.1 Examen general

10.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

10.2.1 CORE SBS-IF MARKET

10.2.2 SBS-IF

10.2.3 ADJACENT / NON-SPECIFIC MARKET

10.3 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.3.1 PARENTERAL NUTRITION

10.3.2 ANÁLOGO GLP-2

10.4 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPA

10.4.3 ASIA-PACIFIC

10.4.4 EAST MIDDLE Y AFRICA

10.4.5 SOUTH AMERICA

10,5 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.5.1 ANTI-DIARRHEALS

10.5.2 PPIS

10.5.3 ANTÍTICOS

10.6 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPA

10.6.3 ASIA-PACIFIC

10.6.4 Medio Oriente y ÁFRICA

10.6.5 SOUTH AMERICA

10.7 MIDDLE EAST AND AFRICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.7.1 NORTH AMERICA

10.7.2 EUROPA

10.7.3 ASIA-PACIFIC

10.7.4 Aire acondicionado y ÁFRICA

10.7.5 SOUTH AMERICA

11 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE

11.1 Examen general

11.2 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)

11.2.2 FASE DE ADAPTACIÓN

11.2.3 FASE RECOVERY

11.3 MIDDLE EAST AND AFRICA ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPA

11.3.3 ASIA-PACIFIC

11.3.4 Medio Oriente y ÁFRICA

11.3.5 SOUTH AMERICA

11.4 MIDDLE EAST AND AFRICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.4.1 NORTH AMERICA

11.4.2 EUROPA

11.4.3 ASIA-PACIFIC

11.4.4. EAST MIDDLE Y AFRICA

11.4.5 SOUTH AMERICA

11.5 MIDDLE EAST AND AFRICA RECOVERY PHASE IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.5.1 NORTH AMERICA

11.5.2 EUROPA

11.5.3 ASIA-PACIFIC

11.5.4 Medio Oriente y ÁFRICA

11.5.5 SOUTH AMERICA

12 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE

12.1 Examen general

12.2 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

12.2.1 ADULT

12.2.2 PEDIATRIC

12.3 MIDDLE EAST AND AFRICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.3.1 NORTE AMERICA

12.3.2 EUROPA

12.3.3 ASIA-PACIFIC

12.3.4 Aire acondicionado

12.3.5 SOUTH AMERICA

12.4 MIDDLE EAST AND AFRICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.4.1 NORTH AMERICA

12.4.2 EUROPA

12.4.3 ASIA-PACIFIC

12.4.4. EAST MIDDLE Y AFRICA

12.4.5 SOUTH AMERICA

13 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 Examen general

13.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

13.2.1 INTRAVENCION

13.2.2

13.2.3 ORAL

13.2.4 ENTERAL

13.3 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

13.3.1 PN

13.3.2

13.4 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.4.1 NORTE AMERICA

13.4.2 EUROPA

13.4.3 ASIA-PACIFIC

13.4.4 Aire acondicionado y ÁFRICA

13.4.5 SOUTH AMERICA

13.5 MIDDLE EAST AND AFRICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.5.1 NORTE AMERICA

13.5.2 EUROPA

13.5.3 ASIA-PACIFIC

13.5.4 Medio Oriente y ÁFRICA

13.5.5 SOUTH AMERICA

13.6 MIDDLE EAST AND AFRICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.6.1 NORTE AMERICA

13.6.2 EUROPA

13.6.3 ASIA-PACIFIC

13.6.4 Medio Oriente y ÁFRICA

13.6.5 SOUTH AMERICA

13.7 MIDDLE EAST AND AFRICA ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.7.1 NORTH AMERICA

13.7.2 EUROPA

13.7.3 ASIA-PACIFIC

13.7.4 Medio Oriente y ÁFRICA

13.7.5 SOUTH AMERICA

14 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER

14.1 Examen general

14.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

14.2.1 HOSPITALS (ACUTE CARE)

14.2.2 Home CARE (Programas de HPN)

14.2.3 SETTINGS ICU

14.2.4 CENTROS PECIALTY GI

14.2.5 PEDIATRIC SPECIALTY HOSPITALS

14.3 MIDDLE EAST AND AFRICA HOSPITALS (ACUTE CARE) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.3.1 NORTE AMERICA

14.3.2 EUROPA

14.3.3 ASIA-PACIFIC

14.3.4 Medio Oriente y ÁFRICA

14.3.5 SOUTH AMERICA

14.4 MIDDLE EAST AND AFRICA HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.4.1 NORTH AMERICA

14.4.2 EUROPA

14.4.3 ASIA-PACIFIC

14.4.4 ORIENTE MEDIO Y ÁFRICA

14.4.5 SOUTH AMERICA

14.5 MIDDLE EAST AND AFRICA ICU SETTINGs in TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.5.1 NORTE AMERICA

14.5.2 EUROPA

14.5.3 ASIA-PACIFIC

14.5.4 Medio Oriente y ÁFRICA

14.5.5 SOUTH AMERICA

14.6 MIDDLE EAST AND AFRICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.6.1 NORTE AMERICA

14.6.2 EUROPA

14.6.3 ASIA-PACIFIC

14.6.4 Medio Oriente y ÁFRICA

14.6.5 SOUTH AMERICA

14.7 MIDDLE EAST AND AFRICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.7.1 NORTH AMERICA

14.7.2 EUROPA

14.7.3 ASIA-PACIFIC

14.7.4 Medio Oriente y ÁFRICA

14.7.5 SOUTH AMERICA

15 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 Examen general

15.2 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

15.2.1 HOSPITAL PHARMACY

15.2.2 PHARMACY ESPECIAL

15.2.3 RETAIL PHARMACY

15.2.4 PHARMACY ONLINE

15.3 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.3.1 NORTE AMERICA

15.3.2 EUROPA

15.3.3 ASIA-PACIFIC

15.3.4 ORIENTE MEDIO Y ÁFRICA

15.3.5 SOUTH AMERICA

15.4 MIDDLE EAST AND AFRICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.4.1 NORTH AMERICA

15.4.2 EUROPA

15.4.3 ASIA-PACIFIC

15.4.4 ORIENTE MEDIO Y ÁFRICA

15.4.5 SOUTH AMERICA

15.5 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.5.1 NORTE AMERICA

15.5.2 EUROPA

15.5.3 ASIA-PACIFIC

15.5.4 ORIENTE MEDIO Y ÁFRICA

15.5.5 SOUTH AMERICA

16 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION

16,1 MIDDLE EAST AND AFRICA

16.1.1 ARABIA SAUDIO

16.1.2 SOUTH AFRICA

16.1.3 EGIPTO

16.1.4 ISERAEL

16.1.5 EMIRATES DE LAS NACIONES UNIDAS

16.1.6 KUWAIT

16.1.7 OMAN

16.1.8 QATAR

16.1.9 BAHRAIN

16.1.10 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST AND AFRICA MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE

17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL

18 ANALISIS SWOT

19 PROFILES DE EMPRESA

19.1 FRESENIUS KABI

19.1.1 SNAPSHOT

19.1.2 ANÁLISIS REVENIDO

19.1.3 COMPANY SHARE ANALISIS

19.1.4 PRODUCTO PORTFOLIO

19.1.5 DESARROLLO RECIENTE

19.2 BAXTER INTERNATIONAL INC.

19.2.1 SNAPSHOT COMPANY

19.2.2 ANÁLISIS REVENIDO

19.2.3 COMPANY SHARE ANALISIS

19.2.4 PRODUCTO PORTFOLIO

19.2.5 DESARROLLO RECIENTE

19.3 NESTLÉ HEALTH SCIENCE

19.3.1

19.3.2 ANÁLISIS REVENIDO

19.3.3 COMPANY SHARE ANALISIS

19.3.4 PRODUCTO PORTFOLIO

19.3.5 DESARROLLO RECIENTE

19.4 LABORATORIAS ABBOTT

19.4.1

19.4.2 ANÁLISIS REVENIDO

19.4.3 COMPANY SHARE ANALISIS

19.4.4 PRODUCTO PORTFOLIO

19.4.5 DESARROLLO RECIENTE

19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITADA

19.5.1 SNAPSHOT

19.5.2 ANÁLISIS REVENIDO

19.5.3 ANÁLISIS DE COMPANÍA

19.5.4 PRODUCTO PORTFOLIO

19.5.5 DESARROLLO RECIENTE

19.6 MOOG COMPANY

19.6.1 SNAPSHOT

19.6.2 ANÁLISIS REVENIDO

19.6.3 PRODUCTO PORTFOLIO

19.6.4 RECENT DEVELOPMENT/NEWS

19.7 ACULIFE HEALTHCARE

19.7.1

19.7.2 PRODUCTO PORTFOLIO

19.7.3 DESARROLLO RECIENTE

19.8 AMSINO INTERNATIONAL, INC

19.8.1 SNAPSHOT

19.8.2 PRODUCTO PORTFOLIO

19.8.3 DESARROLLO RECIENTE

19.9 AURORA

19.9.1

19.9.2 PRODUCTO PORTFOLIO

19.9.3 DESARROLLO RECIENTE

19.1 AMERIPHARMA Cuidado especial.

19.10.1 SNAPSHOT

19.10.2 PRODUCTO PORTFOLIO

19.10.3 DESARROLLO RECIENTE

19.11 Principales empresas de salud

19.11.1

19.11.2 ANÁLISIS REVENIDO

19.11.3 PRODUCTO PORTFOLIO

19.11.4 DESARROLLO RECIENTE

19.12 VELIGROSAS DIGESTIVE CARE

19.12.1

19.12.2 PRODUCTO PORTFOLIO

19.12.3 DESARROLLO RECIENTE

19.13 B. BRAUN SE

19.13.1

19.13.2 PRODUCTO PORTFOLIO

19.13.3 DESARROLLO RECIENTE

19.14 CAMVITTA

19.14.1

19.14.2 PRODUCTO PORTFOLIO

19.14.3 DESARROLLO RECIENTE

19.15 CHOICE PARENTERAL NUTRITION LLC

19.15.1

19.15.2 PRODUCTO PORTFOLIO

19.15.3 DESARROLLO RECIENTE

19.16 CONTINUUMRX

19.16.1

19.16.2 PRODUCTO PORTFOLIO

19.16.3 DESARROLLO RECIENTE

19.17 PHARMACEUTICAS

19.17.1

19.17.2 PRODUCTO PORTFOLIO

19.17.3 DESARROLLO RECIENTE

19.18 GRIFOLS S.A.

19.18.1

19.18.2 ANÁLISIS REVENIDO

19.18.3 PRODUCTO PORTFOLIO

19.18.4 DESARROLLO RECIENTE

19.19 PHARMACEUTICAS HIKMA

19.19.1

19.19.2 ANÁLISIS REVENIDO

19.19.3 PRODUCTO PORTFOLIO

19.19.4 DESARROLLO RECIENTE

19.2 HOSPIRA (PART OF PFIZER INC.)

19.20.1

19.20.2 ANÁLISIS REVENIDO

19.20.3 PRODUCTO PORTFOLIO

19.20.4 DESARROLLO RECIENTE

19.21 HANMI PHARM.CO.,LTD.

19.21.1

19.21.2 ANÁLISIS REVENIDO

19.21.3 PRODUCTO PORTFOLIO

19.21.4 DESARROLLO RECIENTE

19.22 MEDICAL DE UCI, INC.

19.22.1

19.22.2 ANÁLISIS REVENIDO

19.22.3 PRODUCTO PORTFOLIO

19.22.4 DESARROLLO RECIENTE

19.23 SOLUCIONES DE INFUSIÓN

19.23.1

19.23.2 PRODUCTO PORTFOLIO

19.23.3 DESARROLLO RECIENTE

19.24 SISTEMAS DE CARE INTEGRAADOS

19.24.1 SNAPSHOT

19.24.2 PRODUCTO PORTFOLIO

19.24.3 DESARROLLO RECIENTE

19.25 JEDUX PARENTERAL PRIVATE LIMITADA

19.25.1

19.25.2 PRODUCTO PORTFOLIO

19.25.3 DESARROLLO RECIENTE

19.26 LABORATOIRE DIELEN

19.26.1 SNAPSHOT COMPANY

19.26.2 PRODUCTO PORTFOLIO

19.26.3 DESARROLLO RECIENTE

19.27 NAPO THERAPEUTICS.

19.27.1

19.27.2 PRODUCTO PORTFOLIO

19.27.3 RECENT DEVELOPMENT/NEWS

19.28 NUTREGO

19.28.1 SNAPSHOT

19.28.2 PRODUCTO PORTFOLIO

19.28.3 DESARROLLO RECIENTE

19.29 NUTRICIA (Grupo de Dinamarca)

19.29.1 SNAPSHOT

19.29.2 ANÁLISIS REVENIDO

19.29.3 PRODUCTO PORTFOLIO

19.29.4 DESARROLLO RECIENTE

19.3 NUTRICIA NORTH AMERICA

19.30.1

19.30.2 PRODUCTO PORTFOLIO

19.30.3 DESARROLLO RECIENTE

19.31 NUTRISHARE

19.31.1

19.31.2 PRODUCTO PORTFOLIO

19.31.3 DESARROLLO RECIENTE

19.32 OXTHERA

19.32.1

19.32.2 PRODUCTO PORTFOLIO

19.32.3 DESARROLLO RECIENTE

19.33 PHARMKO, INC.

19.33.1

19.33.2 PRODUCTO PORTFOLIO

19.33.3 DESARROLLO RECIENTE

19.34 PUERTO LIFE SCIENCES PVT. LTD.

19.34.1 COMPANY SNAPSHOT

19.34.2 PRODUCTO PORTFOLIO

19.34.3 DESARROLLO RECIENTE

19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.

19.35.1 SNAPSHOT COMPANY

19.35.2 PRODUCTO PORTFOLIO

19.35.3 DESARROLLO RECIENTE

19.36 Cuidado de la salud permanente

19.36.1

19.36.2 PRODUCTO PORTFOLIO

19.36.3 DESARROLLO RECIENTE

19.37 UF HEALTH

19.37.1

19.37.2 PRODUCTO PORTFOLIO

19.37.3 DESARROLLO RECIENTE

19.38 PHARMACEUTICAS IRONWOOD

19.38.1

19.38.2 ANÁLISIS REVENIDO

19.38.3 PRODUCTO PORTFOLIO

19.38.4 DESARROLLO RECIENTE

19.39 VISION PARENTERAL

19.39.1 COMPANY SNAPSHOT

19.39.2 PRODUCTO PORTFOLIO

19.39.3 DESARROLLO RECIENTE

19.4 ZEALAND PHARMA

19.40.1

19.40.2 ANÁLISIS REVENIDO

19.40.3 PRODUCTO PORTFOLIO

19.40.4 DESARROLLO RECIENTE

20 CUESTIÓN

21 INFORMES CONEXOS

Lista de Tablas

CUADRO 1 TREATMENTO DE LOS PACIENTES DEL OSE-IF

CUADRO 2 POBLACIONES PACIENTES ESTIMADAS

Cuadro 3

TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET

TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE MIDDLE EAST and AFRICA TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK

CUADRO 6 DISTRIBUCIÓN DE PRODUCTOS Y PROYECTOS POR MEDIO DE PEQUEÑOS EAST Y AFRICA TYPE 1 MERCADO SBS-IF

CUADRO 7 DISTRIBUCIÓN DE LOS PROYECTOS POR EL APROBADO CIENTÍFICO Y LA FASE – EL ORIENTE MEDIO Y EL MERCADO ÁFRICA 1 SBS-IF

CUADRO 8 DISTRIBUCIÓN DE LOS PROYECTOS POR EL ÁREA Y LA FASE THERAPEUTICOS - MEDIO EAST Y AFRICA TYPE 1 SBS-IF MARKET

CUADRO 9 PIPELINE LANDSCAPE Y DESARROLLO CLINICO

CUADRO 10 TÉCNICAS BASADAS EN LA GLANCE R Pulido – MEDIO EAST Y AFRICA TYPE 1 SBS-IF TREATMENT MARKET

CUADRO 11 CANDIDATOS PRECLINICOS/RESEARCH

TABLE 12 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 13 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 14 MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 16 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 17 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 18 MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 19 MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 20 MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 21 MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 22 MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 23 MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 24 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 25 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 26 MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 27 MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 28 MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 29 MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 30 MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 31 MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 32 MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 33 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 34 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 35 MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 36 MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 37 MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 38 MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 40 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 41 MIDDLE EAST AND AFRICA SURGICAL ' INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 42 MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA SURGICAL ' INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 48 MIDDLE EAST Y AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 51 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 55 MIDDLE EAST Y AFRICA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 57 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA ACUTE PHASE (TYPE 1 SBS-IF) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 59 MIDDLE EAST AND AFRICA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 61 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 63 MIDDLE EAST AND AFRICA PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 64 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 65 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 66 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 67 MIDDLE EAST AND AFRICA SUBCUTANEOUS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 68 MIDDLE EAST AND AFRICA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 69 MIDDLE EAST AND AFRICA ENTERAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 70 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 71 MIDDLE EAST AND AFRICA HOSPITALS (ACUTE CARE) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 72 MIDDLE EAST AND AFRICA HOME CARE (HPN PROGRAMS) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 73 MIDDLE EAST AND AFRICA ICU SETTINGS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 74 MIDDLE EAST AND AFRICA SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 75 MIDDLE EAST AND AFRICA PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 76 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 77 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 78 MIDDLE EAST AND AFRICA SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 79 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

TABLE 80 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

TABLE 81 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 82 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 83 MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 84 MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 85 MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 86 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 87 MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 88 MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 89 MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 90 MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 91 MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 92 MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 93 MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 94 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 95 MIDDLE EAST AND AFRICA HORMONAL & INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 96 MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 97 MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 98 MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 99 MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 100 MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 101 MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 102 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 103 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 104 MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 105 MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 106 MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 107 MIDDLE EAST AND AFRICA BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 109 MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 110 MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 111 MIDDLE EAST AND AFRICA OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 112 MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 MIDDLE EAST AND AFRICA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 114 MIDDLE EAST AND AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 115 MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 116 MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 117 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 118 MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 119 MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 120 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 121 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 122 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 123 MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 124 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 125 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 126 USD

TABLE 127 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 128 ARABIA SAUDITA NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)

TABLE 129 SAUDI ARABIA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 130 SAUDI ARABIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 131 SAUDI ARABIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 132 SAUDI ARABIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 133 ARABIA SAUDITA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 134 SAUDI ARABIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 135 SAUDI ARABIA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 136 SAUDI ARABIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 137 SAUDI ARABIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 138 SAUDI ARABIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 139 ARABIA SAUDIO Terapia PHARMACOLOGICA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 140 SAUDI ARABIA HORMONAL " INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (USTED)

CUADRO 141 ARABIA SAUDITA GLP-2 ANÁLOGO EN TÍPEO 1 SBS-IF (SÍNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 142 SAUDI ARABIA GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)

CUADRO 143 ARABIA SAUDIO IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 144 SAUDI ARABIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 145 SAUDI ARABIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 146 SAUDI ARABIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 147 SAUDI ARABIA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 SAUDI ARABIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 149 ARABIA SAUDIO H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 150 SAUDI ARABIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 151 SAUDI ARABIA ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

TABLE 152 SAUDI ARABIA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 SAUDI ARABIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 SAUDI ARABIA SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 155 SAUDI ARABIA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 156 SAUDI ARABIA OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 157 SAUDI ARABIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 158 ARABIA SAUDIO EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 159 SAUDI ARABIA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 SAUDI ARABIA MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 SAUDI ARABIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 162 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 163 SAUDI ARABIA CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 164 SAUDI ARABIA SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 165 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 166 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 167 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 168 ARABIA SAUDIO INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 169 SAUDI ARABIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 170 ARABIA SAUDITA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 171 USD

TABLE 172 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 173 SOUTH AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 174 SOUTH AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 175 SOUTH AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 SOUTH AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 SOUTH AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 178 SOUTH AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 179 SOUTH AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 SOUTH AFRICA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 SOUTH AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 182 MACRONUTRIENTES SURÁFRICA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 183 MICRONUTRIENTES SUR ÁFRICA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 SOUTH AFRICA PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 185 SOUTH AFRICA HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 186 ANALOGOS SUR ÁFRICA GLP-2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 187 SOUTH AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 188 SOUTH AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 189 SOUTH AFRICA ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 190 SOUTH AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 191 SOUTH AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 192 INHIBITORES SUR AFRICA PROTON EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 193 ANÁLOGO SUR ÁFRICA SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)

TABLE 194 SOUTH AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 195 SUPLEMENTACIÓN MICRONUTRIENTE SURICA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) MERCADO DE TRATAMIENTO, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 196 SOUTH AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 SOUTH AFRICA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 198 SOUTH AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 199 TREATMENTOS SURGICOS Y INTERVENTIONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 200 PROCEDIMIENTOS INTESTINALES DE LENGTHENING EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 201 OSTOMÍA SUR ÁFRICA " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 SOUTH AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 203 SOUTH AFRICA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 204 SOUTH AFRICA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 SOUTH AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 206 SOUTH AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 207 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 208 SOUTH AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 209 SOUTH AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 210 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 211 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 212 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 213 SOUTH ÁFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 214 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 215 SOUTH AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 216 USD

TABLE 217 EGIPTO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 218 EGYPT NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 219 EGYPT PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 EGYPT TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 221 EGYPT HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 222 EGIPTO HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 223 EGIPTO ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 224 EGIPTO TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 225 EGYPT FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 226 EGIPTO PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 227 EGYPT MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 228 EGIPTO MICRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 EGYPT PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 EGIPTO HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 231 ANALOGOS EGIPTO GLP-2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 232 EGYPT GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 233 EGIPTO IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 234 EGYPT ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 235 EGIPTO OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 EGYPT ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 237 EGIPTO PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 238 EGIPTO SOMATOSTATIN ANALOGUES EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (US$ THOUSAND)

CUADRO 239 ANTAGONISTAS EGIPTO H2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 240 EGYPT MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 EGIPTO ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 EGYPT BILE ACID " ABSORPERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 243 EGIPTO BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 244 EGYPT SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 245 PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 246 EGIPTO OSTOMY " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 247 EGYPT INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 EGIPTO EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 249 MEDICINA REGENERATIVO EGIPTO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 250 EGYPT MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 EGYPT GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 252 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 253 EGIPTO CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 254 EGIPTO SBS-IF EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 255 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 256 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 257 EGYPT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 258 EGIPTO INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 259 EGIPTO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 260 EGIPTO TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 261 USD

TABLE 262 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 263 ISRAEL NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 ISRAEL PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 265 ISRAEL TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 266 ISRAEL HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 267 ISRAEL HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 268 ISRAEL ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 269 ISRAEL TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 270 ISRAEL FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 271 COMPOSICIÓN DE PN ISRAEL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 272 ISRAEL MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 273 MICRONUTRIENTS ISRAEL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 274 ISRAEL PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 275 ISRAEL HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 276 ANALOGOS ISRAEL GLP-2 en TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 277 ISRAEL GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 278 ISRAEL IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 279 ISRAEL ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 280 ISRAEL OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 281 ISRAEL ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 282 INHIBITORES DE PROTOMAS DE ISRAEL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 283 ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (USTED THOUSAND)

TABLE 284 ISRAEL H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 285 SUPLEMENTO MICRONUTRIENT EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 286 ISRAEL ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 287 MODIFICADORES DE ABSORPCIÓN DE ISRAEL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 288 SEQUESTRANTES DE IRAEL ACID EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 289 TREATMENTO SURGICO " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 290 PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 291 OSTOMÍA DE ISRAEL " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 292 ISRAEL INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 293 ISRAEL EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 294 ISRAEL REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 295 ISRAEL MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 ISRAEL GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 298 ISRAEL CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 299 SBS-IF ATRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 300 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 301 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 302 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 303 ISRAEL INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 304 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 305 ISRAEL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 306 USD

CUADRO 307 EMIRATES DE ARAB TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 308 EMIRATES DE ARAB NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 309 EMIRATES PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 310 EMIRATES TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 311 EMIRATOS ÁRABES INICIO PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 312 EMIRATES ÁRABES INICIO PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 313 EMIRATES ÁRABES ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 314 EMIRATES DE LAS NACIONES UNIDAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 315 EMIRATES DE LAS NACIONES UNIDAS PARAMULA TYPE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 316 UNITED ARAB EMIRATES PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 317 EMIRATES DE LAS NACIONES UNIDAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 318 MICRONUTRIENTES DE LAS NACIONES UNIDAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 319 EMIRATES DE ÁRABES PHARMACOLOGICA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 320 EMIRATES ÁRABES HORMONAL " INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 321 EMIRATES ÁRABES GLP-2 ANÁLOGO EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 322 EMIRATES ÁRABES GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 323 EMIRATES ÁRABES IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 324 EMIRATES ÁRABES ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 325 EMIRATES ÁRABES OPIOID-BASED EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 326 EMIRATES ÁRABES ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 327 DE EMIRATOS ÁRABES DE PROTONos EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 328 EMIRATOS ÁRABES SOMATOSTATIN ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 329 UNITED ARAB EMIRATES H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 330 EMIRATES MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 331 EMIRATES ÁRABES ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 332 EMIRATES ÁRABES BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SYNDROME BOWEL con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)

CUADRO 333 EMIRATES DE ÁRABES BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 334 DE EMIRATOS ÁRABES SURGICOS " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 335 EMIRATES DE LAS NACIONES UNIDAS DE LENGTHENING INTESTINAL PROCEDURES EN TYPE 1 SBS-IF (SYNDROME DE BOWEL con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (USTED)

CUADRO 336 EMIRATES DE LA OSTOMÍA " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 337 EMIRATES DE LAS NACIONES UNIDAS EN TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 338 EMIRATOS ÁRABES EMERGING " AVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 339 EMIRATES REGENERATIVE MEDICINE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 340 EMIRATES ÁRABES MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 341 UNITED ARAB EMIRATES GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 342 EMIRATES DE LAS NACIONES UNIDAS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 343 UNITED ARAB EMIRATES CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 344 EMIRATES DE ÁRABES DE SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 345 EMIRATES DE ARAB TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 346 UNITED ARAB EMIRATES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 347 EMIRATES DE ARAB TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 348 EMIRATES DE LAS NACIONES UNIDAS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 349 EMIRATES DE LAS NACIONES UNIDAS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 350 EMIRATES DE ARAB TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 351 USD

TABLE 352 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 353 KUWAIT NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 354 KUWAIT PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 355 KUWAIT TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 356 KUWAIT HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 357 KUWAIT HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 358 KUWAIT ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

TABLE 359 KUWAIT TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 360 KUWAIT FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 361 KUWAIT PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 362 KUWAIT MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 363 KUWAIT MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 364 KUWAIT PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 365 KUWAIT HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 KUWAIT GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 367 KUWAIT GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 368 KUWAIT IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 369 KUWAIT ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 370 KUWAIT OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 371 KUWAIT ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 KUWAIT PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 373 KUWAIT SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 374 KUWAIT H2 RECEPTOR ANTAGONISTS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 375 KUWAIT MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 KUWAIT ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 KUWAIT BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 378 KUWAIT BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 KUWAIT SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 380 KUWAIT INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 381 KUWAIT OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 382 KUWAIT INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 383 KUWAIT EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 KUWAIT REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 385 KUWAIT MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 386 KUWAIT GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 387 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 388 KUWAIT CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 389 KUWAIT SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 390 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 391 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 392 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 393 KUWAIT INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 394 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 395 KUWAIT TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 396 USD

TABLE 397 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 398 OMAN NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

CUADRO 399 DE PARENTERAL OMAN NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 400 OMAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 401 OMAN HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 402 OMAN HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 403 NUTRICIÓN ENTERAL OMAN (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 404 OMAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 405 OMAN FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 406 OMAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 407 MACRONUTRIENTS OMAN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 408 MICRONUTRIENTS OMAN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 409 OMAN PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

CUADRO 410 OMAN HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 411 ANALOGOS OMAN GLP-2 EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 412 OMAN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 413 OMAN IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 414 ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 415 OMAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 416 ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

CUADRO 417 INHIBIdores OMAN PROTON PUMP en TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 418 ANÁLOGO OMAN SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USTED THOUSAND)

CUADRO 419 ANTAGONISTAS DE H2 OMAN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 420 SUPLEMENTO OMAN MICRONUTRIENT EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 421 OMAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 422 MODIFICADORES DE ACID DE ABSORPCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 423 ACID SEQUESTRANTS OMAN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 424 TREATMENTO SURGICANO OMAN " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 425 PROCEDIMIENTOS DE LENGTHENING OMAN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 426 OMAN OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 427 TRANSPLANTACIÓN OMAN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 428 OMAN EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 429 OMAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 430 OMAN MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 431 OMAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 432 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 433 OMAN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 434 OMAN SBS-IF ATRIBUTABLE MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 435 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 436 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 437 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 438 OMAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 439 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 440 OMAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 441 USD

TABLE 442 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 443 QATAR NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 444 QATAR PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 445 QATAR TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 446 QATAR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 447 QATAR HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 448 QATAR ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

TABLE 449 QATAR TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 450 QATAR FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 451 QATAR PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 452 QATAR MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 453 QATAR MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 454 QATAR PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 455 QATAR HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 456 ANALOGOS QATAR GLP-2 EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 457 QATAR GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 458 QATAR IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 459 QATAR ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 460 QATAR OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 461 QATAR ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 462 QATAR PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 463 ANÁLOGOS QATAR SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)

CUADRO 464 QATAR H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 465 QATAR MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 466 QATAR ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 467 QATAR BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 468 QATAR BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 469 QATAR SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 470 PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 471 OSTOMÍA QATAR " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 472 QATAR TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 473 QATAR EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 474 QATAR REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 475 QATAR MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 476 QATAR GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 477 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 478 QATAR CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 479 QATAR SBS-IF EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 480 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 481 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 482 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 483 QATAR INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 484 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 485 QATAR TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 486 USD

TABLE 487 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 488 BAHRAIN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 489 BAHRAIN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 490 BAHRAIN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 491 BAHRAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 492 BAHRAIN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 493 BAHRAIN ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 494 BAHRAIN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 495 BAHRAIN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 496 BAHRAIN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 497 BAHRAIN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 498 MICRONUTRIENTS BAHRAIN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 499 BAHRAIN PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 500 BAHRAIN HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 501 BAHRAIN GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 502 BAHRAIN GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 503 BAHRAIN IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 504 BAHRAIN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 505 BAHRAIN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 506 BAHRAIN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 507 BAHRAIN PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 508 BAHRAIN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 509 BAHRAIN H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 510 BAHRAIN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 511 BAHRAIN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 512 BAHRAIN BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 513 BAHRAIN BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 514 TRATAMIENTO SURGICO e INTERVENTIONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 515 BAHRAIN PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 516 BAHRAIN OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 517 BAHRAIN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 518 BAHRAIN EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 519 BAHRAIN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 520 BAHRAIN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 521 BAHRAIN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 522 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 523 BAHRAIN CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 524 BAHRAIN SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 525 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 526 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 527 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 528 BAHRAIN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 529 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 530 BAHRAIN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 531 USD

CUADRO 532 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 533 REST OF MIDDLE EAST AND AFRICA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 534 REST OF MIDDLE EAST AND AFRICA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 535 REST OF MIDDLE EAST AND AFRICA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 536 REST OF MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 537 REST OF MIDDLE EAST AND AFRICA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 538 REST OF MIDDLE EAST AND AFRICA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 539 REST OF MIDDLE EAST AND AFRICA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 540 REST OF MIDDLE EAST AND AFRICA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 541 REST OF MIDDLE EAST AND AFRICA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 542 REST OF MIDDLE EAST AND AFRICA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 543 REST OF MIDDLE EAST AND AFRICA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 544 REST OF MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 545 REST OF MIDDLE EAST AND AFRICA HORMONAL ' INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 546 REST OF MIDDLE EAST AND AFRICA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 547 REST OF MIDDLE EAST AND AFRICA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 548 REST OF MIDDLE EAST AND AFRICA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 549 REST OF MIDDLE EAST AND AFRICA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 550 REST OF MIDDLE EAST AND AFRICA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 551 REST OF MIDDLE EAST AND AFRICA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 552 REST OF MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 553 REST OF MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 554 REST OF MIDDLE EAST AND AFRICA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 555 REST OF MIDDLE EAST AND AFRICA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 556 REST OF MIDDLE EAST AND AFRICA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 557 REST OF MIDDLE EAST AND AFRICA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 558 REST OF MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 559 REST OF MIDDLE EAST AND AFRICA SURGICAL & INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 560 REST OF MIDDLE EAST AND AFRICA INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 561 REST OF MIDDLE EAST AND AFRICA OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 562 REST OF MIDDLE EAST AND AFRICA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 563 REST OF MIDDLE EAST AND AFRICA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 564 REST OF MIDDLE EAST AND AFRICA REGENERA MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 565 REST OF MIDDLE EAST AND AFRICA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 566 REST OF MIDDLE EAST AND AFRICA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 567 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 568 REST OF MIDDLE EAST AND AFRICA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 569 REST OF MIDDLE EAST AND AFRICA SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 570 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

CUADRO 571 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 572 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 573 REST OF MIDDLE EAST AND AFRICA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 574 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 575 REST OF MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

Lista de figuras

FIGURE 1 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: MIDDLE EAST and AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING

FIGURE 10 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE

FIGURE 11 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID

FIGURE 12 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 13 FOUR SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)

FIGURE 14 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.

FIGURE 16 NUTRITIONAL SUPPORT THERAPY is EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033

FIGURE 17 DECISIONES STRATEGIC

FIGURE 18 PESTEL ANALISIS

FIGURE 19 ANALISIS DROC

FIGURE 20 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025

FIGURE 21 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025

FIGURE 22 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025

FIGURE 23 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025

FIGURE 24 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025

FIGURE 25 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025

FIGURE 26 MIDDLE EAST and AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025

FIGURE 27 MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 28 MIDDLE EAST AND AFRICA MIDDLE EAST AND AFRICA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

Ver información detallada

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Medio Oriente y África Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East And Africa Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

Tasa de crecimiento anual compuesta (CAGR) : 6.90 %

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)Tamaño

Ámbito de presentación de informesTipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Medio Oriente y África Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento Dinámica del mercado

Medio Oriente y África Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Medio Oriente y África Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Los últimos desarrollos en Oriente Medio y África Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Tabla de contenido

Lista de Tablas

Lista de figuras

Metodología de investigación

Personalización disponible

Informes relacionados con la industria